RT Journal Article
SR Electronic
T1 Prevalence and impact of small airways dysfunction in patients with ischemic heart disease
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2154
VO 44
IS Suppl 58
A1 Claudia Llontop
A1 Almudena Castro
A1 Regina Dalmau
A1 Cristina Garcia
A1 Sandra Rojas
A1 Carlos Carpio
A1 David Romero
A1 Raul Galera
A1 Joan Soriano
A1 Francisco Garcia Rio
A1 Rodolfo Alvarez Sala
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2154.abstract
AB Objectives: To identify the prevalence of small airways dysfunction (SAD) in stable patients with ischemic heart disease (IHD), to characterize the factors associated with SAD and evaluates its clinical impact.Methods: 118 patients, active or ex-smokers with a previous diagnosis of IHD were evaluated. We recorded the comorbidity, degree of angina, cardiac function, cardiovascular risk and quality of life. Pre- and post-bronchodilator spirometry, determination of airway resistance by forced oscillation/impulse oscillometry (IOS), two-compartment analysis of exhaled nitric oxide and systemic biomarkers were performed in all patients. We consider as airflow limitation (AFL) a post-bronchodilator FEV1/FVC <0.7 and as SAD a R5-20 or a Z5 higher to the upper limits of normality.Results: The three study groups (control, SAD and AFL) were homogeneous. AFL prevalence was 28.0% (CI95%:19.9-36.1) and 45.8% of SAD (36.8-54.8). Male gender, BMI and GOLD screener questionnaire score were independent determinants of SAD in the IHD group. There were no differences between control and SAD groups in terms of degree of angina, NYHA class and systolic function. The SAD group had higher cardiovascular risk (Frammingham Risk in control group: 7.0 ± 1.9, SAD: 8.3 ± 2.4 and AFL: 8.8 ± 2.4, p = 0.006) and worse quality of life (physical function, general health and physical component domains) than control group and similar to patients with AFL. Similarly, the hsCRP was higher in the AFL and SAD groups than in the control group.Conclusions: The SAD is highly prevalent in patients with ischemic heart disease and is associated with increased systemic inflammation and cardiovascular risk and poorer quality of life.